Clinical Trials List
2013-12-01 - 2019-12-31
Phase III
Terminated10
ICD-10NoDx
0
ICD-9E942.2
Antilipaemic and antiarteriosclerotic drugs causing adverse effects in therapeutic use
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/19
Investigators and Locations
Co-Principal Investigator
- Lien-Cheng Hsiao Division of Cardiovascular Diseases
- 林晏年 Division of Cardiovascular Diseases
- 盧炯睿 Division of Cardiovascular Diseases
- 謝禮全 Division of Cardiovascular Diseases
- 王宇澄 Division of Cardiovascular Diseases
- 吳宏彬 Division of Cardiovascular Diseases
- Po-Yen Ko Division of Cardiovascular Diseases
- 張志斌 Division of Cardiovascular Diseases
- Pei-Ying Pai Division of Cardiovascular Diseases
- 陳業鵬 Division of Cardiovascular Diseases
- 陳恬恩 Division of Cardiovascular Diseases
- Shih-Sheng Chang Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wen-Chung Yu Division of Cardiovascular Diseases
- Shih-Hsien Sung Division of Cardiovascular Diseases
- Tse-Min Lu Division of Cardiovascular Diseases
- 林幸榮 Division of Cardiovascular Diseases
- Kang-Ling Wang Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 蔡瑞鵬 Division of Cardiovascular Diseases
- 藍偉仁 Division of Cardiovascular Diseases
- 蔡政廷 Division of Cardiovascular Diseases
- 顏志軒 Division of Cardiovascular Diseases
- 林岳鴻 Division of Cardiovascular Diseases
- 張盛雄 Division of Cardiovascular Diseases
- 劉俊傑 Division of Cardiovascular Diseases
- 余法昌 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Cheng-Han Lee Division of Cardiovascular Diseases
- Yi-Heng Li Division of Cardiovascular Diseases
- Ting-Hsing Chao Division of Cardiovascular Diseases
- Ping-Yen Liu Division of Cardiovascular Diseases
- 李貽恆 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 劉俊傑 Division of Cardiovascular Diseases
- 余法昌 Division of Cardiovascular Diseases
- 林岳鴻 Division of Cardiovascular Diseases
- 張盛雄 Division of Cardiovascular Diseases
- 蔡瑞鵬 Division of Cardiovascular Diseases
- 藍偉仁 Division of Cardiovascular Diseases
- 蔡政廷 Division of Cardiovascular Diseases
- 顏志軒 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
175 participants
-
Global
6300 participants
